Literature DB >> 11448466

Ovarian function during use of vaginal rings delivering three different doses of Nestorone.

V Brache1, D R Mishell, P Lahteenmaki, F Alvarez, K Elomaa, T Jackanicz, A Faundes.   

Abstract

Contraceptive vaginal rings delivering various progestins alone or in combination with estrogen have been previously studied, showing adequate steroid vaginal absorption and acceptability by the users. Nestorone progestin (NES) is a potent 19-nor-progesterone derivative, inactive by the oral route, but an excellent option for vaginal delivery. The purpose of this study was to evaluate ovarian function during 6 months of continuous use of progestin-only vaginal rings delivering 3 different doses of NES: 50, 75, and 100 microg per day. Blood samples were taken twice a week for 5 consecutive weeks during a control cycle and on months 1, 3 and 6 of use, for the measurement of estradiol (E2), progesterone (P), and NES. A total of 87 volunteers randomly received each of the 3 doses. After an initial peak, NES serum levels remained fairly constant throughout the duration of the study at about 125, 200 and 250 pmol/L, respectively, decreasing slightly with time. Luteal activity occurred very rarely (1.2-2.6% of sampling periods) with no apparent difference between doses. Low E2 levels (< or =100 pmol/L) in all samples of a run were rare (5%) and only with the high dose ring (100 microg/day). E2 remained within normal levels (101-1500 pmol/L) in most of the segments studied. We conclude that the 50 and 75 microg/day NES rings provide adequate ovulation inhibition without hypoestrogenism, while the 100 microg/day ring may deliver an unnecessarily high dose.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11448466     DOI: 10.1016/s0010-7824(01)00199-8

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  8 in total

1.  Continuous dosing of a novel contraceptive vaginal ring releasing Nestorone® and estradiol: pharmacokinetics from a dose-finding study.

Authors:  J T Jensen; A B Edelman; B A Chen; D F Archer; K T Barnhart; M A Thomas; A E Burke; C L Westhoff; L S Wan; R Sitruk-Ware; N Kumar; B Variano; D L Blithe
Journal:  Contraception       Date:  2018-02-02       Impact factor: 3.375

Review 2.  New progestogens: a review of their effects in perimenopausal and postmenopausal women.

Authors:  Régine Sitruk-Ware
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

3.  Preventing secondary exposure to women from men applying a novel nestorone/testosterone contraceptive gel.

Authors:  F Yuen; S Wu; A Thirumalai; R S Swerdloff; S T Page; P Y Liu; C Dart; H Wu; D L Blithe; R Sitruk-Ware; J Long; F Bai; L Hull; W J Bremner; B D Anawalt; C Wang
Journal:  Andrology       Date:  2018-12-16       Impact factor: 4.456

Review 4.  Pharmacokinetics, metabolism and serum concentrations of progestins used in contraception.

Authors:  Alexis J Bick; Renate Louw-du Toit; Salndave B Skosana; Donita Africander; Janet P Hapgood
Journal:  Pharmacol Ther       Date:  2020-12-13       Impact factor: 13.400

Review 5.  Intravaginal rings as delivery systems for microbicides and multipurpose prevention technologies.

Authors:  Andrea Ries Thurman; Meredith R Clark; Jennifer A Hurlburt; Gustavo F Doncel
Journal:  Int J Womens Health       Date:  2013-10-21

6.  Fourth-Generation Progestins Inhibit 3β-Hydroxysteroid Dehydrogenase Type 2 and Modulate the Biosynthesis of Endogenous Steroids.

Authors:  Renate Louw-du Toit; Meghan S Perkins; Jacky L Snoep; Karl-Heinz Storbeck; Donita Africander
Journal:  PLoS One       Date:  2016-10-05       Impact factor: 3.240

7.  Dose-finding study of a 90-day contraceptive vaginal ring releasing estradiol and segesterone acetate.

Authors:  Melissa J Chen; Mitchell D Creinin; David K Turok; David F Archer; Kurt T Barnhart; Carolyn L Westhoff; Michael A Thomas; Jeffrey T Jensen; Bruce Variano; Regine Sitruk-Ware; Anita Shanker; Jill Long; Diana L Blithe
Journal:  Contraception       Date:  2020-05-19       Impact factor: 3.375

Review 8.  New and emerging contraceptives: a state-of-the-art review.

Authors:  Luis Bahamondes; M Valeria Bahamondes
Journal:  Int J Womens Health       Date:  2014-02-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.